Improving Clinical Decision Making with Engaging CME, Tools, & Resources
Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD
Diana V. Do, MD
Peter K. Kaiser, MD
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Arshad M. Khanani, MD, MA
Karl Csaky, MD, PhD
Christina Y. Weng, MD, MBA, FASRS
GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data
Theodore Leng, MD, MS
Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation
Cara Dolin, MD
Jennifer Simpson
Diana Girnita, MD ,PhD
A Closer Look at Real-World Strategies for Treatment-Resistant DME
Durga Borkar, MD, MMCi
Reducing Retina Treatment Burden in the Real World: Emerging Evidence with Treatment Advances
Jayanth Sridhar, MD
Sabin Dang, MD
Clinical Evidence for Durable Treatment of nAMD
Real-World Outcomes with Durable Treatments for Retinal Diseases
Extending Treatment Durability With Next-Generation Neovascular AMD Therapies
A Look at the Numbers: Cost of Durable Treatments in Retinal Disease
Clinical Evidence for Durable Treatment of DME
Reconsidering the Algorithm: nAMD
Reconsidering the Algorithm: DME
Impacts on Access to Eye Care: Key Socioeconomic Factors
Mario R. Nacinovich, Jr., MSc
Sally L. Baxter, MD, MSc
Discussing Drug Diversion: An Exploration of Impact & Prevention Through Smart Data
Charles Turck, PharmD, BCPS, BCCCP
Michael LaFauci
Jeffrey Wahl
Concerns in the Community: Obstacles to Accessing the COVID-19 Vaccine
Hector O. Chapa, MD, FACOG
Robert Owens Carpenter, MD, MPH, FACS, FASMBS
Toni E. Keaton, MD, MPH
Loading...
We’re glad to see you’re enjoying Eye Health Academy… but how about a more personalized experience?
Press cancel to remain on Eye Health Academy. Press the link below or the continue button to keep going.